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Abstract
Background: Oncogenic activation of the PI3K signalling pathway plays a pivotal role in the development of glioblastoma
multiforme (GBM). A central node in PI3K downstream signalling is controlled by the serine-threonine kinase AKT1. A
somatic mutation affecting residue E17 of the AKT1 gene has recently been identified in breast and colon cancer. The E17K
change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited
to target the PI3K pathway. Assessing whether AKT1 is activated by somatic mutations in GBM is relevant to establish its role
in this aggressive disease.
Methodology/Principal Findings: We performed a systematic mutational analysis of the complete coding sequence of the
AKT1 gene in a panel of 109 tumor GBM samples and nine high grade astrocytoma cell lines. However, no somatic
mutations were detected in the coding region of AKT1.
Conclusions/Significance: Our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve
somatic mutations in the coding region of AKT1.
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Introduction
A number of genetic and functional evidences have unequiv-
ocally established the importance of the PI3K pathway in human
cancer [1,2]. For example oncogenic deregulation of the PI3K
pathway plays a central role in the development of Glioblastoma
Multiforme (GBM) as shown by the fact that many of its members
are genetically altered [3,4]. Two main regulators, the lipid kinase
PIK3CA and the lipid phosphatase PTEN, control this signalling
pathway. We and other have shown that the PIK3CA gene is
mutated in many tumour types, including GBM [4–7]. The
corresponding mutations result in activation of the PI3K catalytic
activity and constitutive downstream signalling. The tumour
suppressor gene PTEN encodes for a lipid phopshatase which
counteracts the effect of PI3K thus negatively controlling
signalling. PTEN is mutationally and transcriptionally inactivated
in many different tumour types, including GBM [8]. In most
tumour lineages, including GBMs PIK3CA and PTEN mutations
occur in a mutually exclusive manner [6,9]. This suggests that they
exert overlapping cellular functions, and in fact, both control the
cellular levels of phosphatidylinositol-3-phosphate (PIP3) [10,11].
Other mechanisms of activation of the PI3K pathway include
alterations in tyrosine kinase receptors acting upstream in the
signalling cascade. This is the case for the receptor tyrosine kinase
EGFR which can be activated by gene amplification and/or
mutations [12]. Both missense point mutations and large
extracellular domain deletions (EGFRvIII, which due to alternative
splicing misses exon 2–7) affecting the EGFR gene have been
reported at considerable frequency in GBM and result in
constitutive activation of the receptor and of the underlying
PI3K pathway [12].
Downstream in the signaling cascade, PI3K and PTEN control
PIP3, which activates downstream effector molecules, such as the
serine-threonine kinase AKT. A recent sequencing study led to the
identification of oncogenic somatic mutations in the pleckstrin
homology domain of AKT1 in breast, colon and ovarian cancer
[13]. Interestingly, in all cases examined the same mutation E17K
was identified. This mutation alters the electrostatic interactions of
the pocket and constitutively activates AKT1 in a PI3K-
independent manner. By this mechanism, it transforms rodent cells
in vitro and can induce leukaemia in mice [13]. Recently, we and
others assessed the mutational status of the E17K mutation in
different tumor types [14–17], confirming the mutations in breast
and colon, andmost interestingly revealingmutations in lung cancer
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[14,15]. On the contrary, we did not detect any mutations affecting
the hotspot residue E17 in a panel of 128 GBMs [15]. We noted
that, GBMs do exhibit a different mutation spectrum for some genes
compared to other tumor types. For example, most EGFR and
ERBB2 mutations in lung cancer are found in the kinase domain
[18,19], whereas these genes are predominantly mutated in the
extracellular domain in GBM [12,20]. This led us to speculate that
GBMs might bear mutations in other regions of the AKT1 gene. To
definitively assess this hypothesis, we successfully sequenced the
complete coding sequence of AKT1 in 109 GBM tumor samples and
nine high grade astrocytoma cell lines.
Results and Discussion
We sequenced the complete coding sequence of the AKT1 gene in
a set of 109 GBM tumors and 9 high grade astrocytoma cell lines.
Primers were designed to amplify and sequence the genomic region
corresponding to all coding exons of AKT1, including exon 4, where
the E17K residue is located. Amplicons included at least 15 intronic
bases at both the 59 and 39 ends encompassing the splicing donor
and acceptor sites. A total of 1535 PCR products, spanning 628 kb
of tumour genomic DNA, were generated and subjected to direct
sequencing. Sequencing was performed single stranded with either
forward or reverser primer. Identified changes were independently
confirmed by another round of PCR and sequencing.
Previous work focusing on the mutational analysis of exon 4 did
not identify any E17K mutation in 128 GBM samples [15].
Importantly, we extended the mutational analysis for these tumors
to all other coding exons of AKT1, but no somatic mutations were
found.
Our tumor set was validated by previous mutational profiling of
common cancer genes, including the IDH1 gene [21]. Further-
more, we found a number of previous reported SNPs in our
samples (rs17846822, rs34664585, rs3730358, rs3730368,
rs2494737, rs2494735, rs34670300, rs3730361, rs3730329,
rs3730329, rs2494732). In addition, we identified three novel
germline changes (IVS8-12C.T, R200H and W333*) at low
frequency, they were found only once in different samples. Our
work is focused on somatic mutations and therefore, we did not
study these changes in further detail.
While previous studies have focused mainly on the hotspot
mutation site AKT1E17or the serine and threonine phosphorylation
sites [3,15,17], this work is the first to show in a large panel of
GBMs that the coding sequence of the AKT1 is not somatically
mutated in this tumour lineage. Although the promoter region
and/or the 59 and 39 UTR of AKT1 may contain mutations, our
data indicate that in GBM oncogenic deregulation of the PI3K
pathway does not involve mutations in the coding region of AKT1.
Materials and Methods
Tumor sample, Ethics Statement and Isolation of
Genomic DNA
All samples were collected from patients undergoing brain
tumor surgery in the Academic Medical Center (Amsterdam, The
Netherlands). Oral consent for removal of the tissue and its storage
in the tumor bank for research purposes was obtained and
documented in the patient’s medical chart. Individual consent for
this specific project was waivered by our ethics committee because
the research was performed on ‘waste’ material, stored in a coded
fashion. Patient characteristics are displayed in Table 1. Tumor
samples were included only if at least 80% of the sample consisted
of cancer cells, as verified by H&E staining.
Nine astrocytoma cell lines were included: the cell lines
U87MG, U118MG, U251MG, U373MG, T98G (ATCC, Mid-
dlesex, United Kingdom), SKMG-3 (a gift of Dr Christopher Y.
Thomas, University of Virginia Division of Hematology/Oncol-
ogy, Charlottesville, VA), SF763 (gift of Dr M.L. Lamfers,
Table 1. Characteristics of 109 GBM tumor samples.
GBM subclasses primary 94
secondary 15
Patient sex female 47
male 62
Patient age mean age (years) 53.6
median age (years) 55
doi:10.1371/journal.pone.0005638.t001
Table 2. Primer details to sequence the coding sequence of AKT1.
Exon Forward Primer Sequence Reverse Primer Sequence Sequencing Primer Sequence
3 GTCAGAGAGCTTAGAGGGATGG GGCACAGGCACTCACAGA AGTGGGTCTCTGGCTCACC
4 AGTCTGCCTTCCCGTTGAC CAGCCAGTGCTTGTTGCTT GTTTCTGTCGCTGGCCCTA
5 AGGCTTGGAGAGAGGAAGAGAT GGAGTGAGGATGGCTACAGG CTGGTGGGTGGTATGCAAG
6 AGGGCTGTCTCTGGGAACC TGGAGTGCTGAGTGTCTCCTG GGGTGGGTGAAAGACGTG
7 GTTCCCTGTAAGCCTGGACTC TAAAGCAGGGCTGGGTGA GCTCTGCCTCCGACTCTG
8 CCGCTACTACGCCATGAAGA ACATCGTCCCCTAGAGACAGC CATGAAGATCCTCAAGAAGGAAG
9 AACACTCCTTGGCACCTCAG TAACTCAGCAGGAACAAGTCACC ATCAGGCGACGTGGTATCAA
10 AGTTAGGGCTTCTGAGACTTTCC CTTGTCCAGCATGAGGTTCTC GTCCCTTCCCTGTGCAATG
11 CTACCTGCACTCGGAGAAGAAC CAGGACTCGGCATCAAGG GCACAGAGAGGACACAGCATT
12 CTGAGCACACGCAATGCT GACATCAAGCTTTGGCTATCAGT AATGCTGTGTCCTCTCTGTGC
13 GTGAGCTCTGTGGTGCTTTG GCGTGAGTGTGGATATGTGG GCCCTACATCACAGGAGGAA
14 GCTTGCTGCTCTCTGACATC AGGCCTCTCTGAGTGTGGA ATCCAGGTGCTTTGAAGGTCT
15 AGGTCCCTGTGTCAATCTGTG CTCAAATGCACCCGAGAAATA GAGGTTGGCTTCCTACTGGAG
Primers in 59 to 39 direction.
doi:10.1371/journal.pone.0005638.t002
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Department of Neurosurgery, Free University, Amsterdam, The
Netherlands), SF126 (a gift of Dr C. Van Bree, University of
Amsterdam, Laboratory for Experimental Oncology and Radia-
tion Biology, Amsterdam, The Netherlands), Gli-6 was derived
from our own laboratory. Genomic DNA was isolated as
previously described [22].
PCR, Sequencing and Analysis
PCR primers were designed using Primer 3 (http://frodo.wi.
mit.edu/cgi-bin/primer3/primer3_www.cgi), and synthesized by
Invitrogen/Life Technologies, Inc. (Paisley, England) (Table 2).
PCR primers that amplify the selected exons and the flanking
intronic sequences, including splicing donor and acceptor regions,
were used and PCR products were on average 381 bps in length.
PCRs were performed in both 384- and 96-well formats in 5- or
10-uL reaction volumes, respectively, containing 0.25 mmol/L
deoxynucleotide triphosphates, 1 umol/L each of the forward and
reverse primers, 6% DMSO, 16PCR buffer, 1 ng/uL DNA, and
0.05 unit/uL Platinum Taq (Invitrogen/Life Technologies). A
touchdown PCR program was used for PCR amplification (Peltier
Thermocycler, PTC-200, MJ Research, Bio-Rad Laboratories,
Inc., Italy).
PCR conditions were as follows: 94uC for 2 min; three cycles of
94uC for 15 s, 64uC for 30 s, 70uC for 30 s; three cycles of 94uC
for 15 s, 61uC for 30 s, 70uC for 30 s; three cycles of 94uC for
15 s, 58uC for 30 s, 70uC for 30 s; and 35 cycles of 94uC for 15 s,
57uC for 30 s, and 70uC for 30 s, followed by 70uC for 5 min and
12uC thereafter. PCR products were purified using AMPure
(Agencourt Bioscience Corp., Beckman Coulter S.p.A, Milan,
Italy). Cycle sequencing was carried out using BigDye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA)
with an initial denaturation at 97uC for 3 min, followed by 28
cycles of 97uC for 10 s, 50uC for 20 s, and 60uC for 2 min.
Sequencing products were purified using CleanSeq (Agencourt
Bioscience, Beckman Coulter) and analyzed on a 3730 DNA
Analyzer, ABI capillary electrophoresis system (Applied Biosys-
tems). Sequence traces were analyzed using the Mutation Surveyor
software package (SoftGenetics, State College, PA).
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